1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > 2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800.

VPGMarketResearch’s new report is a study of the major business opportunities emerging in the European cancer diagnostics market during the next five years. The report examines trends in major European countries; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Geographic Coverage

France, Germany, Italy, Spain, UK

European Market Overview

- Five-year test volume and sales projections by country.

- Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country.

- Estimated universe of laboratories performing cancer diagnostic testing by country.

- Cancer statistics, etiology and recent developments.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains, and others.

- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major cancer diagnostic product suppliers by individual test and country.

- Five-year test volume and sales forecasts for major tumor markers by country and market segment, including:

- Hospitals
- Commercial/Private Laboratories
- Physician Offices/Group Practices

Instrumentation Review

- Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

- Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

- Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

- Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

- Companies analyzed in the report include:

   - Abbott
   - AdnaGen
   - Agilent Technologies
   - Applied Gene Technologies
   - Arca Biopharma
   - Beckman Coulter/Danaher
   - Becton Dickinson
   - Biomedical Diagnostics
   - bioMerieux
   - Bio-Rad
   - CellSearch
   - Cepheid
   - Correlogic Systems/Vermillion
   - Decode Genetics
   - Diadexus
   - Diagnocure
   - DiaSorin
   - Eiken Chemical
   - Elitech Group
   - Enterix
   - Enzo Biochem
   - Epigenomics
   - Exact Sciences
   - Fujirebio
   - Guided Therapeutics
   - Hologic/Gen-Probe
   - Kreatech/Leica
   - Kyowa Medex
   - Mackay Life Sciences
   - Myriad Genetics
   - OncoLab
   - Ortho-Clinical Diagnostics
   - Panacea Pharmaceuticals
   - Polartechnics
   - Polymedco
   - PreMD
   - Qiagen
   - Quest Diagnostics
   - Radient Pharmaceuticals
   - Roche
   - Scienion
   - Sequenom
   - Siemens Healthcare
   - Takara Bio
   - Targeted Diagnostics & Therapeutics
   - Thermo Fisher
   - Tosoh
   - Veridex
   - Wako Pure Chemicals
   - Wallac/PE
   - Zilla

Contains 820 pages and 320 tables

Table Of Contents

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK
Table of Contents
I. Introduction II.
Worldwide Market Overview 1. Market Overview 2. Worldwide Market Structure 3. Worldwide Market Size and Growth
III. Major Product Development Opportunities A. Reagent Kits and Test Systems/Panels B. Instrumentation C. Computers, Software and Automation D. Auxiliary Products
IV. Design Criteria for Decentralized Testing Products V. Alternative Market Penetration Strategies A. Internal Development B. Collaborative Arrangements C. University Contracts D. Distribution Strategies
VI. Potential Market Entry Barriers and Risks A. Market Maturity B. Cost Containment C. Competition D. Technological Edge and Limitations E. Patent Protection F. Regulatory Constraints G. Decentralized Testing Market Challenges

VII. Worldwide Market and Technology Overview A. Cancer Statistics and Etiology 1. Breast Cancer 2. Lung Cancer 3. Colon and Rectum Cancer 4. Prostate Cancer 5. Stomach Cancer 6. Leukemia 7. Lymphoma 8. Oral Cancer 9. Skin Cancer 10. Uterine Cancer 11. Ovarian Cancer 12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction 2. Tumor Marker Classification 3. ACTH 4. Alpha-Fetoprotein (AFP) 5. Beta-2 Microglobulin 6. CA 15-3/27.29 7. CA 19-9 8. CA-125 9. Calcitonin 10. Carcinoembrionic Antigen (CEA) 11. Estrogen and Progesterone Receptors 12. Ferritin 13. Gastrin 14. Human Chorionic Gonadotropin (HCG) 15. Insulin 16. NSE 17. Occult Blood 18. PAP Smear/HPV 19. Prostatic Acid Phosphatase (PAP) 20. Prostate-Specific Antigen (PSA) 21. Squamous Cell Carcinoma Antigen (SCC) 22. T and B Lymphocytes

23. TdT 24. Thyroglobulin 25. Tissue Polypeptide Antigen (TPA) 26. Biochemical Tumor Markers 27. Oncogenes - Abl/abl-bcr - AIB1 - BCL-2 - BRCA1 - CD44 - C-fos - C-myb - C-myc - CYP-17 - Erb-B - HPC1 - N-myc - P40 - P51 - P53 - PIK3CA - PTI-1 - Ras - Reg - Sis - Src 28. Polypeptide Growth Factors - Basic Fibroblast Growth Factor - Beta-TGF - Cachectin (TNT) - Calmodulin - ECFR - Nerve Growth Factor (NGF) - Epidermal Growth Factor (EGF) - Ornithine Decarboxylase - Transferrin - Transforming Growth Factor-Alpha

29. Ectopic Hormones 30. Colony Stimulating Factors 31. Lymphokines - Alpha-Interferon - B Cell Growth Factors - B Cell Growth Factor (BCGF) - Gamma-Interferon - Interleukin-1 (IL-1) - Macrophage Activating Factor 32. Immunohistochemical Stains 33. Emerging Tumor Markers - N-Acetylglucosamine - Actin - Alpha-Actin - Antineuronal Antibodies - 7B2 - B72.3 - Bax - BCD-F9 - BLCA-4 - Blood Group Antigens A,B,H - CA 50 - CA 72-4/TAG-72 - CA 195 - CA-242 - CA-549 - CAM 26 - CAR-3 - Cathepsin-D - Chromogranin A and B - Cluster 1 Antigen - Cluster-5/5A Antigen - CTA - CU18 - DR-70 - DU-PAN-2 - Endometrial Bleeding Associated Factor - Endostatin - Epithelial Membrane Antigen - Feulgen Hydrolysis - Fibronectin

- FSH - (1->3)-L-fucosyltransferase - Gastrin-Releasing Peptide (GRP) - GDCFP-15 - Glucagon - Glycoamines - H23 - Her-2 - Human Carcinoma Antigen - HPA - HSP27 - Intermediate Filaments - Cytokeratins/CK18/Cyfra 21-1 - Desmin - Gliofibrillary Acid Protein - Neurofilaments - Vimentin - KA 93 - Kinases - KP16D3 - LAI - Leukocyte Common Antigen - Lewis Antigens - Lysophosphatidic Acid (LPA) - Ma 695/Ma 552 - MABDF3 - MAG - ME1 - Minactivin - MN/CA9 - MSA - Mucin Cancer Antigen (MCA) - Multiple Tumor Suppressor 1 - Myosin - NEA-130 - NMP22 - OA-519 - Opioid Peptides - P-glycoprotein - Pancreatic Oncofetal Antigen (POA) - Placental Lactogen - PR92
- Proliferative Index, Ki-67 - Px - RB Inactivation/Deletion - Ret - SCCL 175 - Selectin - Sialic Acid - Sialyl SSEA-1/SLX - SN10 - Somatostatin - TA-90 - TABA - Tachykinin - TAG 12 - TPS - Troponin - Tubulin - VCAM - VEGF - Villen
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
1. Monoclonal and Polyclonal Antibodies 2. Immunoassays 3. Molecular Diagnostics 4. Chromosome Analysis a. Chronic Myelogenous Leukemia (CML) b. Acute Myeloid Leukemia (AML) c. Acute Lymphoblastic Leukemia (ALL) d. Malignant Lymphomas Lymphoid Malignancies e. Chronic Lymphocytic Leukemia (CLL) f. Solid Cancers g. Chromosomal Translocation and Oncogenes 5. Artificial Intelligence 6. Flow Cytometry 7. Two Dimensional Gel Electrophoresis (2-DGE) 8. Biosensors 9. Competing/Complementing Technologies
E. Personal Testing

VIII. France Cancer Diagnostics Market A. Executive Summary B. Business Environment C. Market Structure D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test
IX. Germany Cancer Diagnostics Market A. Executive Summary B. Business Environment C. Market Structure D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test
X. Italy Cancer Diagnostics Market A. Executive Summary B. Business Environment C. Market Structure D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test
XI. Japan Cancer Diagnostics Market A. Executive Summary B. Business Environment C. Market Structure D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test
XII. Spain Cancer Diagnostics Market A. Executive Summary B. Business Environment C. Market Structure D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test

XIII. U.K. Cancer Diagnostics Market
A. Executive Summary B. Business Environment C. Market Structure D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test
XIV. U.S. Cancer Diagnostics Market
A. Executive Summary B. Business Environment C. Market Structure D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test
XV. Competitive Profiles
- Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Enterix - Enzo Biochem - Epigenomics - Exact Sciences

- Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics and Therapeutics - Tosoh - Thermo - Veridex - Wako Pure Chemicals - Wallac/PE - Zila XVI. Appendix: Major Universities and Research Centers Developing Cancer Diagnostic Technologies and Applications
List of Tables
Tumor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
List of Tables (continues)
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer Diagnosis
Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

  • $ 75000
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both ...

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...


Download Unlimited Documents from Trusted Public Sources

Insulin Market and Diabetes Statistics in the US

  • March 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Diabetes Statistics

  • March 2017
    10 pages
  • Diabetes  

    Therapy  

View report >

Hormone and Therapy Market in Pakistan and the US

  • March 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.